Back to dashboard
Episode 104
DIP Episode 104 - ACLS, Arrhythmias, and HY Cardiac Pharm
PharmacologyMedium4 - HighHas Q&A
Step 1Step 2Step 3COMLEXMedicineUSMLEStep 1Step 2Step 3
Topic
ACLS protocols (V-fib, VTach, PEA); Antiarrhythmic drug classes and mechanisms; Cardiovascular pharmacology (ACEi, Beta-blockers, Calcium Channel Blockers).
Key Takeaway
Mastering the ACLS algorithm requires remembering that every two minutes, you must perform a pulse check/rhythm check, shock if indicated for V-fib/VTach, and administer an antiarrhythmic drug (Epi/Amiodarone) based on the rhythm.
Runtime: 41.8 min
Published: 2019-05-23
Completed audio: Yes
Completed notes: Yes
Anki made: No
Section: INTERNAL MEDICINE
Episode Notes
Source / episode info
- Episode: 104
- Title: Divine Intervention Episode 104 – ACLS, Arrhythmias, and HY Cardiac Pharm
- Published: 2019-05-23
- Source: Episode page
One-liner
This episode provides a comprehensive review of Advanced Cardiac Life Support (ACLS) protocols for various rhythms and details high-yield cardiac pharmacology, including antiarrhythmic drug classes, ACE inhibitor renal protection mechanisms, and the complex mechanism of digoxin toxicity.
High-yield summary
- V-fib/Pulseless V Tach: This is a shockable rhythm requiring immediate defibrillation (unsynchronized cardioversion) every 2 minutes. The protocol involves CPR, rhythm check, shocking, and administering drugs (Epinephrine 1mg, then Amiodarone).
- PEA/Asystole: These are non-shockable rhythms managed by high-quality CPR and repeated administration of Epinephrine (1mg), with no need for defibrillation or antiarrhythmics like Amiodarone.
- Stable V Tach: Managed primarily with IV medications (e.g., beta-blockers, non-dihydropyridine CC Bs) to control rate/rhythm; synchronized cardioversion is reserved if the patient becomes unstable.
- ACE Inhibitors (AC Ei): Used in heart failure and renal protection because they decrease Angiotensin II formation, thereby preventing excessive constriction of the efferent arteriole and reducing intraglomerular hypertension.
- Digoxin Toxicity: The mechanism involves Digoxin blocking the Na+/K+ AT Pase pump; this leads to intracellular accumulation of sodium, which secondarily impairs the Na+/Ca exchanger, causing elevated cardiac calcium and increased contractility (and toxicity). Hypocalcemia increases susceptibility to digoxin toxicity.
Learning objectives
- Describe the systematic approach to ACLS management, differentiating between shockable (V-fib/V Tach) and non-shockable rhythms (PEA/Asystole).
- Identify appropriate antiarrhythmic drugs based on rhythm stability and type of tachycardia (e.g., rate control vs. rhythm control).
- Explain the pathophysiology of ACE inhibitors in preventing renal damage by modulating efferent arteriolar tone.
- Detail the mechanism of digoxin toxicity, recognizing that hypocalcemia increases susceptibility to poisoning.
- Differentiate between synchronized cardioversion (for stable/unstable tachyarrhythmias) and unsynchronized defibrillation (for V-fib).
Board exam buzzwords
| Condition | Key Finding | Association | Board Exam Tip |
| V-Fibrillation | Pulseless, chaotic rhythm | Unsynchronized Cardioversion (Defibrillation) | Always remember the 3 steps every 2 minutes: Pulse check/Rhythm check -> Shock if indicated -> Drug. |
| ACE Inhibitors | Decreased Angiotensin II | Efferent arteriolar constriction prevention | Use in diabetic nephropathy or chronic HTN to prevent intraglomerular hypertension. |
| Digoxin Toxicity | Nausea, GI upset, arrhythmias | Na+/K+ AT Pase pump inhibition; Hypocalcemia risk | Treat with Digoxin-specific antibody fragments (digibind). |
| Non-Dihydropyridine CC Bs | Peripheral edema, reflex tachycardia | Vasodilation of post-capillary venules -> increased capillary hydrostatic pressure. | Verapamil/Diltiazem are used for rate control in stable tachyarrhythmias. |
Rapid review table
| Topic | Key Point | Context | Exam Relevance |
| ACLS: V-fib | Unsynchronized Cardioversion (Defibrillation) every 2 min. | Pulseless, chaotic rhythm; requires immediate energy delivery. | High yield for board exams; remember the precise drug sequence and timing. |
| ACE Inhibitors | Protects kidneys by maintaining efferent arteriolar tone. | Diabetic nephropathy/Chronic HTN. | Classic question stem: "Which agent prevents intraglomerular hypertension?" |
| Digoxin Toxicity | Hypocalcemia increases risk; treated with digibind. | Na+/K+ AT Pase pump inhibition -> impaired Na+/Ca exchanger. | Must know the mechanism and antidote to distinguish it from other cardiac poisons. |
| Beta-Blockers (HF) | Metoprolol, Carvedilol, Bisoprolol improve survival. | H FrEF management; must be initiated early. | Only these three specific drugs are proven to reduce mortality in HF. |
Board-speak -> diagnosis
| Board-speak / Vignette phrase | Diagnosis / Concept | Why it fits |
| A patient in V-fib is unresponsive. The team performs CPR, checks the rhythm every 2 minutes, and delivers an electrical shock. | V-Fibrillation (V-fib) Management | V-fib requires unsynchronized cardioversion/defibrillation every two minutes. Remember the sequence: Check -> Shock -> Drug. |
| A patient with stable V Tach presents to the ED. The physician initiates IV Diltiazem and Metoprolol. | Stable Tachycardia Management (Rate Control) | Beta-blockers and non-dihydropyridine CC Bs are first-line agents for rate control in stable tachyarrhythmias, avoiding electricity unless unstable. |
| A patient with chronic heart failure is found to have reduced creatinine clearance and elevated blood pressure. The physician starts Lisinopril. | ACE Inhibitor Use (Renal Protection) | AC Ei prevent Angiotensin II from constricting the efferent arteriole, thereby reducing intraglomerular hypertension and protecting the kidney. |
| A patient with a narrow-complex tachycardia is unstable (hypotensive). The initial management involves synchronized cardioversion. | Unstable Tachycardia Management | If any tachyarrhythmia (except V-fib/pulseless V Tach) causes instability, immediate electrical intervention via synchronized cardioversion is required. |
| A cardiac drug that blocks the Na+/K+ AT Pase pump and can cause hyperkalemia if administered in a patient with hypocalcemia. | Digoxin Toxicity Mechanism | Digoxin's mechanism involves blocking this pump; low calcium enhances its effect, leading to toxicity. |
| A patient presents with Paroxysmal Atrial Tachycardia (PAT) that is stable but symptomatic. The physician administers IV Verapamil. | Rate Control in Stable Arrhythmia | Non-dihydropyridine CC Bs and beta-blockers are the preferred agents for rate control when the patient is hemodynamically stable. |
Differential diagnosis / distinguishing features
Cardiac Drugs: AC Ei vs. CC Bs
| Key Features | Distinguishing Findings | Next Step |
| ACE Inhibitors (e.g., Lisinopril): Block conversion of Ang I to Ang II. Dilate post-capillary venules. | Used for renal protection by maintaining efferent arteriolar tone; used in HF/HTN. | First line therapy for HTN and HF, especially with kidney involvement. |
| CC Bs (Non-Dihydropyridine): Block L-type calcium channels. Cause vasodilation of pre-capillary arterioles. | Used for rate control; can cause peripheral edema and reflex tachycardia due to systemic vasodilation. | Use when the primary goal is slowing conduction through the AV node in stable tachyarrhythmias. |
Management pearls
- ACLS Leadership: The code leader must identify themselves, assign specific roles (compressions, defibrillation, recording, timing), and maintain a calm demeanor to set a productive tone.
- CPR Quality: Maintain high-quality chest compressions at a rate of 100–120/min, with depth of 2.4–2.5 inches in adults.
- V-fib Protocol (Every 2 Minutes): Perform rhythm check -> Shock if indicated -> Administer drug (Epi then Amiodarone).
- AC Ei Renal Protection: The mechanism is crucial: AC Ei prevent Angiotensin II from constricting the efferent arteriole, thereby preventing intraglomerular hypertension and subsequent hyperfiltration injury.
Don't miss
🚨
V-fib/Pulseless V Tach (Shockable): Requires unsynchronized cardioversion (defibrillation) every 2 minutes.
🚨
PEA/Asystole (Non-shockable): Management is solely CPR and Epinephrine; do not shock or use Amiodarone.
🚨
Digoxin Toxicity: Hypocalcemia significantly increases the risk of toxicity because it enhances the effect of calcium on the Na+/K+ AT Pase pump.
🚨
Beta-Blockers in HF: Only Metoprolol, Carvedilol, and Bisoprolol have demonstrated improved survival rates in Heart Failure with reduced Ejection Fraction (H FrEF).
Integration & clinical reasoning
- Pharmacology & Renal Physiology: The use of ACE inhibitors to treat peripheral edema associated with CC Bs is a direct pharmacological link. Both agents cause vasodilation; the AC Ei specifically dilates post-capillary venules, mimicking the effect needed to reduce capillary hydrostatic pressure.
- Cardiology & Nephrology: Understanding how Angiotensin II constricts the efferent arteriole (leading to intraglomerular hypertension) is key to understanding why ACE inhibitors are protective in diabetic nephropathy. This links systemic RAAS activity directly to microvascular renal hemodynamics.
- ACLS & Leadership: Effective code management requires clear delegation and adherence to protocols, emphasizing that leadership tone dictates team performance—a critical non-pharmacological skill tested in high-stakes scenarios.
OMM / COMLEX integration
🦴
For COMLEX: know these viscerosomatics / Chapman points, but don't let OMM distract from emergent diagnosis and management.
- Pharmacology & Renal Physiology: Understanding how ACE inhibitors treat peripheral edema associated with CC Bs provides a direct link between cardiovascular pharmacology (vasodilation) and nephrology (fluid balance). Both mechanisms involve dilating post-capillary venules, which reduces capillary hydrostatic pressure.
- Cardiology & Nephrology: The concept of efferent arteriolar constriction by Angiotensin II is central to understanding why ACE inhibitors are protective in diabetic nephropathy. This links systemic RAAS activity directly to microvascular renal hemodynamics.
- ACLS & Leadership: Effective code management requires clear delegation and adherence to protocols, emphasizing that leadership tone dictates team performance—a critical non-pharmacological skill tested in high-stakes scenarios.
Concept connections / cross-references
- No explicit cross-references.
High-yield association table
| Condition | Association | Mechanism | Clinical Significance |
| Digoxin Toxicity | Hypocalcemia risk | Low Ca enhances the effect of Ca on Na+/K+ AT Pase pump. | Always check serum calcium levels before administering digoxin in high-risk patients (e.g., those on diuretics). |
| ACE Inhibitors | Reduced intraglomerular pressure | Prevents Ang II from constricting the efferent arteriole. | Primary agent for renal protection in diabetic nephropathy and chronic HTN. |
| CC Bs (Non-Dihydropyridine) | Peripheral edema, reflex tachycardia | Vasodilation of post-capillary venules -> increased capillary hydrostatic pressure. | The mechanism explains why AC Ei can also treat the peripheral edema caused by these drugs. |
| Digoxin | Hyperkalemia risk | Blocks Na+/K+ AT Pase pump (prevents K+ reabsorption). | Monitor potassium levels, especially when combined with potassium-sparing diuretics. |
Key terms glossary
| Term | Definition | Context | Example |
| Synchronized Cardioversion | Electrical shock delivered timed to the R wave of the QRS complex. | Used for unstable tachyarrhythmias (e.g., V Tach) to avoid R-on-T phenomenon. | Delivering a jolt when the patient's heart is repolarizing at the peak of the T wave would be dangerous. |
| Unsynchronized Cardioversion | Electrical shock delivered without timing relative to the cardiac cycle. | Used for V-fib or pulseless V Tach, where chaotic electrical activity makes timing irrelevant. | Defibrillating a patient in V-fib requires maximum energy delivery regardless of underlying rhythm. |
| Efferent Arteriole | The vessel leaving the glomerulus (capillary tuft). | Constriction here increases glomerular hydrostatic pressure. | ACE inhibitors prevent this constriction, protecting the kidney from hyperfiltration injury. |
| Na+/K+ AT Pase Pump | Primary active transport pump that moves 3 Na+ out and 2 K+ in. | Inhibition leads to intracellular accumulation of sodium and impaired calcium handling. | Digoxin inhibits this pump; hypocalcemia increases its sensitivity, leading to toxicity. |
Study optimization
| Topic | Study Approach | Priority | Resources |
| ACLS Protocols | Flowchart memorization (V-fib -> PEA/Asystole) and drug timing. | High (Board Exam Critical) | Review the latest AHA guidelines; practice rapid recall of drug doses and intervals. |
| Cardiac Pharmacology | Mechanism of action (MOA) for all major classes (AC Ei, CC Bs, Digoxin). | Medium-High (Step 1/2 Integration) | Focus on why a drug is used (e.g., AC Ei -> efferent arteriole; Beta-blocker -> H FrEF survival). |
| Arrhythmia Management | Stable vs. Unstable decision tree for all tachyarrhythmias. | High (Board Exam Critical) | Create flowcharts: Is the patient stable? If yes, rate control drugs. If no, cardioversion/anti-fibrinolytic agents. |
Question pattern recognition
- The "Why" Question: Instead of asking what drug to give, expect questions about the underlying pathophysiology (e.g., Why is AC Ei used in diabetic nephropathy?).
- Differentiating Shockable vs. Non-Shockable: Always confirm if a rhythm requires unsynchronized defibrillation or only CPR/drugs.
- Drug Mechanism Traps: Be prepared to link drug side effects directly back to their molecular mechanism (e.g., Digoxin -> Na+/K+ AT Pase pump).
Test yourself
Common mistakes to avoid
🚫
Confusing Cardioversion Types: Mistaking synchronized cardioversion for unsynchronized defibrillation, leading to inappropriate energy delivery during stable V Tach (must use sync shock).
🚫
Mismanaging PEA/Asystole: Attempting to shock a pulseless rhythm (PEA/Asystole) or administering Amiodarone when only CPR and Epinephrine are indicated.
🚫
Incorrect Drug Timing in V-fib: Forgetting the specific drug sequence: Epi -> Amiodarone, administered every two minutes.
🚫
Ignoring Stability Status: Failing to assess patient stability before initiating cardioversion; instability dictates immediate electrical intervention.
Common traps
⚠️
The "Why" Question (AC Ei): Expect questions about why ACE inhibitors are used in diabetic nephropathy—the answer is preventing efferent arteriolar constriction, not just lowering blood pressure.
⚠️
Digoxin Mechanism: The trap lies in linking hypocalcemia to increased digoxin toxicity risk because low calcium enhances the effect of calcium on the Na+/K+ AT Pase pump.
⚠️
HF Survival Drugs: Only Metoprolol, Carvedilol, and Bisoprolol have been proven to improve survival in H FrEF; memorizing this specific trio is crucial for board exams.
⚠️
CCB/AC Ei Edema Link: The mechanism of peripheral edema from CC Bs (systemic vasodilation -> increased capillary hydrostatic pressure) must be linked back to the action of AC Ei (dilating post-capillary venules) to understand their therapeutic overlap.